Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody

Blood

Volumn 87, Issue 3, 1996, Pages 893-899

  Knox, Susan ^a   Hoppe, Richard T ^b   Maloney, David ^b   Gibbs, Iris ^b   Fowler, Sherry ^b   Marquez, Carol ^b   Cornbleet, P JoAnne ^b   Levy, Ronald ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CHIMERIC ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; NONSTEROID ANTIINFLAMMATORY AGENT; OKT 4; PARACETAMOL; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; FEVER; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNIZATION; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; LYMPHOCYTE PROLIFERATION; MALE; MYALGIA; MYCOSIS FUNGOIDES; PHASE 1 CLINICAL TRIAL; PHOTOTHERAPY; PRIORITY JOURNAL; RASH; SKIN LYMPHOMA; SUBCUTANEOUS DRUG ADMINISTRATION; T CELL LYMPHOMA; TOPICAL DRUG ADMINISTRATION;

EID: 0030069871     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.3.893.bloodjournal873893     Document Type: Article

References (16)

1. Wood GS, Abel EA, Hoppe RT, Warnke RA: Leu-8 and Leu-9 antigen phenotypes: Immunologic criteria for the distinction of mycosis fungoides from cutaneous inflammation. J Am Acad Dermatol 14:1006, 1986
2. Young RC: Mycosis fungoides: The therapeutic search continues. N Engl J Med 321:1822, 1989
3. Kuzel TM, Roenigk HH, Rosen ST: Mycosis fungoides and the Sezary syndrome: A review of pathogenesis, diagnosis, and therapy. J Clin Oncol 9:1298, 1991
4. Bunn PJ, Hoffman SJ, Norris D, Golitz LE, Aeling JL: Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 121:592, 1994
5. Bertram JH, Gill PS, Levine AM, Boquiren D, Hoffman FM, Meyer P, Mitchell MS: Monoclonal antibody T101 in T cell malignancies: A clinical, pharmacokinetic, and immunologic correlation. Blood 68:752, 1986
6. Dillman RO, Shawler DL, Dillman JB, Royston I: Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 2:881, 1984
7. Miller RA, Oseroff AR, Stratte PT, Levy R: Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62:988, 1983
8. Knox SJ, Levy R, Hodgkinson S, Bell R, Brown S, Wood GS, Hoppe R, Abel EA, Steinman L, Berger RG, Gaiser C, Young G, Bindl J, Hanham A, Reichert T: Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 77:20, 1991
9. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB: Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 86:4220, 1989
10. Bindl JM, Warnke RA: Advantages of detecting monoclonal antibody binding to tissue sections with biotin and avidin reagents in Coplin jars. Am J Clin Pathol 85:490, 1986
11. Elkins KL, Stashak PW, Baker PJ: Analysis of the optimal conditions for the adsorption of type III pneumococcal polysaccharide to plastic for use in solid-phase ELISA. J Immunol Methods 130:123, 1990
12. Knox S: Radioimmunotherapy of Non-Hodgkin's lymphoma. Semin Radiat Oncol 5:331, 1995
13. Rosen ST, Zimmer AM, Goldman LR, Kazikiewicz JM. Dykewicz MS, Silverstein EA, Spies SM, Kaplan EH: Progress in the treatment of cutaneous T cell lymphomas with radiolabeled monoclonal antibodies. Int J Rad Appl Instrum [B] 16:667, 1989
14. Raubitschek AA: Yttrium-90 labeled T101 in the treatment of hematologic malignancies. Proceedings of the Fifth International Conference on Monoclonal Antibody Conjugates for Cancer 1990, San Diego, CA
15. Miller RA, Levy R: Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 2:226, 1981
16. 131I-labeled monoclonal antibody: An Illinois Cancer Council Study. J Clin Oncol 5:562, 1987